Purpose: To present a novel case of corneal subepithelial drug deposits secondary to oral niraparib, a newly approved medication for maintenance therapy for ovarian cancer. Methods: Case report. Results: A 73-year-old woman presented to our eye clinic with blurred vision after commencement of oral niraparib. Slit-lamp examination, anterior segment optical coherence tomography, and Scheimpflug tomography demonstrated bilateral predominantly peripheral, subepithelial corneal hyperreflective lesions consistent with drug deposits. Systemic workup excluded paraproteinemic keratopathy. In the presence of concurrent cataracts, the visual impact of these deposits was unclear. Because of ill health, the niraparib treatment was continued by the oncologists, and the ocular conditions were managed conservatively with topical lubrication. No progress of corneal deposits was observed. Conclusions: Niraparib therapy may be associated with corneal drug deposition. The pattern of subepithelial drug deposition seen in this case is distinct to other commonly reported drug deposits.